Literature DB >> 25574453

Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players.

Robert Vincent1, Arun Sanyal1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatis (NASH) are becoming the dominant liver diseases in the US and Western World. Extensive work is being done to diagnose, understand, and explore the pathogenesis of these multivariable complex diseases. Recently a new avenue of biologic regulation is being explored. MicroRNAs are non-coding RNAs that modulate the expression of multiple genes and have been implicated in multiple diseases. Recently there is a growing body of evidence supporting a significant role of microRNAs in NAFLD pathogenesis and progression to NASH, and hinting at their use as targets, biomarkers and potential therapeutic tools. This review is designed to highlight some of the recent work on a few of the key microRNAs involved in the pathogenesis of NAFLD and NASH.

Entities:  

Keywords:  NAFLD; Nonalcoholic fatty liver disease; biologic regulation; biomarkers; miR-122; miR-24; miR-33a; miR-34a; micro-RNA; nonalcoholic steatohepatis; pathogenesis; therapeutic tools

Year:  2014        PMID: 25574453      PMCID: PMC4283847          DOI: 10.1007/s40139-014-0049-8

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  86 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake.

Authors:  Yi Gong; Joon No Lee; Peter C W Lee; Joseph L Goldstein; Michael S Brown; Jin Ye
Journal:  Cell Metab       Date:  2006-01       Impact factor: 27.287

3.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

4.  Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice.

Authors:  Igor P Pogribny; Athena Starlard-Davenport; Volodymyr P Tryndyak; Tao Han; Sharon A Ross; Ivan Rusyn; Frederick A Beland
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

5.  Secreted monocytic miR-150 enhances targeted endothelial cell migration.

Authors:  Yujing Zhang; Danqing Liu; Xi Chen; Jing Li; Limin Li; Zhen Bian; Fei Sun; Jiuwei Lu; Yuan Yin; Xing Cai; Qi Sun; Kehui Wang; Yi Ba; Qiang Wang; Dongjin Wang; Junwei Yang; Pingsheng Liu; Tao Xu; Qiao Yan; Junfeng Zhang; Ke Zen; Chen-Yu Zhang
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

6.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

7.  MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice.

Authors:  Angela Dolganiuc; Jan Petrasek; Karen Kodys; Donna Catalano; Pranoti Mandrekar; Arumugam Velayudham; Gyongyi Szabo
Journal:  Alcohol Clin Exp Res       Date:  2009-07-01       Impact factor: 3.455

8.  Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.

Authors:  Volodymyr P Tryndyak; John R Latendresse; Beverly Montgomery; Sharon A Ross; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-24       Impact factor: 4.219

9.  The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families.

Authors:  Yoshiki Murakami; Hidenori Toyoda; Masami Tanaka; Masahiko Kuroda; Yoshinori Harada; Fumihiko Matsuda; Atsushi Tajima; Nobuyoshi Kosaka; Takahiro Ochiya; Kunitada Shimotohno
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

10.  A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats.

Authors:  Yu-Wen Su; Xi Chen; Zhen-Zhou Jiang; Tao Wang; Cheng Wang; Yun Zhang; Jing Wen; Mei Xue; Dan Zhu; Yue Zhang; Yi-Jing Su; Tong-Yue Xing; Chen-Yu Zhang; Lu-Yong Zhang
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

View more
  10 in total

1.  Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.

Authors:  Da Jung Kim; Hyewon Chung; Sang Chun Ji; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  Metabolomics       Date:  2019-02-27       Impact factor: 4.290

Review 2.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

Review 3.  Factors influencing circulating microRNAs as biomarkers for liver diseases.

Authors:  Shalini R Dubey; Tester F Ashavaid; Philip Abraham; Minal Umesh Paradkar
Journal:  Mol Biol Rep       Date:  2022-02-20       Impact factor: 2.742

Review 4.  Role of MicroRNAs in NAFLD/NASH.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  Dig Dis Sci       Date:  2016-01-14       Impact factor: 3.199

5.  MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis.

Authors:  Aline de Conti; Juliana Festa Ortega; Volodymyr Tryndyak; Kostiantyn Dreval; Fernando Salvador Moreno; Ivan Rusyn; Frederick A Beland; Igor P Pogribny
Journal:  Oncotarget       Date:  2017-08-01

6.  Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells.

Authors:  Young-Sun Lee; So Yeon Kim; Eunjung Ko; Jun-Hee Lee; Hyon-Seung Yi; Yang Jae Yoo; Jihye Je; Sang Jun Suh; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Hyung Joon Yim; Won-Il Jeong; Jong Eun Yeon; Soon Ho Um; Kwan Soo Byun
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

7.  Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitis.

Authors:  Xi Jin; Jiang Liu; Yi-Peng Chen; Zun Xiang; Jie-Xia Ding; You-Ming Li
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

Review 8.  MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  J Clin Med       Date:  2015-05-20       Impact factor: 4.964

9.  Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signaling pathway.

Authors:  Chao Zhou; Pu Wang; Lei Lei; Yi Huang; Yue Wu
Journal:  Aging (Albany NY)       Date:  2020-05-15       Impact factor: 5.682

10.  Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction.

Authors:  Da Jung Kim; Seonghae Yoon; Sang Chun Ji; Jinho Yang; Yoon-Keun Kim; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Jae-Yong Chung; Joo-Youn Cho
Journal:  Sci Rep       Date:  2018-08-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.